Spyre Therapeutics, Inc. (SYRE)
USD 23.16
(-8.31%)
USD 23.16
(-8.31%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -99.91 Million | -80.14 Million | -53.71 Million | -75.77 Million | -65.69 Million | -32.19 Million |
| Net Income | -338.79 Million | -83.81 Million | -65.8 Million | -80.89 Million | -78.25 Million | -44.34 Million |
| Depreciation & Amortization | 744 Thousand | 1.56 Million | 1.57 Million | 996 Thousand | 901 Thousand | 293 Thousand |
| Deferred income taxes | 214.89 Million | -327 Thousand | 548 Thousand | -213 Thousand | - | - |
| Stock-based compensation | 25.67 Million | 7.11 Million | 8.03 Million | 6.25 Million | - | - |
| Change in working capital | -5.2 Million | -5.5 Million | 1.83 Million | -2.54 Million | 7.1 Million | 7.2 Million |
| Other non-cash items | 2.77 Million | 823 Thousand | 90 Thousand | 619 Thousand | 3.77 Million | 1.93 Million |
| Investing Cash Flow | -108.39 Million | 57 Million | -22.61 Million | -7.6 Million | -1.73 Million | -15.23 Million |
| Investments in PPE | - | -38 Thousand | -573 Thousand | -4.28 Million | -1.49 Million | -422 Thousand |
| Acquisitions | 3.03 Million | - | - | - | - | - |
| Investment purchases | -166.8 Million | -39.5 Million | -133.07 Million | -129 Million | -91.92 Million | -62.17 Million |
| Sales/Maturities of investments | 39.9 Million | 96.54 Million | 111.03 Million | 125.67 Million | 91.67 Million | 47.37 Million |
| Other Investing Activities | 15.47 Million | - | - | - | - | - |
| Financing Cash Flow | 361.07 Million | 42.67 Million | 1.39 Million | 154.51 Million | 65.72 Million | 57.06 Million |
| Debt repayment | -16 Thousand | -418 Thousand | -510 Thousand | -20 Thousand | -25 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 169.11 Million | 42.87 Million | 1.9 Million | 153.71 Million | 65.74 Million | 57.06 Million |
| Other Financing Activities | -5.78 Million | - | - | - | - | - |
| Accounts receivables | 375 Thousand | 440 Thousand | - | - | - | 3.07 Million |
| Accounts payables | 218 Thousand | -2.64 Million | 1.06 Million | -544 Thousand | 2.58 Million | 239 Thousand |
| Inventory | -375 Thousand | -440 Thousand | - | - | - | - |
| Other working capital | -5.42 Million | -2.86 Million | 768 Thousand | -1.99 Million | 4.52 Million | 3.88 Million |
| Cash at beginning of period | 36.41 Million | 16.98 Million | 91.93 Million | 20.75 Million | 22.46 Million | 12.81 Million |
| Cash at end of period | 189.21 Million | 36.41 Million | 16.98 Million | 91.93 Million | 19.25 Million | 22.46 Million |
| Capital Expenditure | - | -38 Thousand | -573 Thousand | -4.28 Million | -1.49 Million | -422 Thousand |
| Effect of forex changes on cash | 25 Thousand | -106 Thousand | -15 Thousand | 51 Thousand | -1.5 Million | - |
| Net cash flow / Change in cash | 152.79 Million | 19.43 Million | -74.95 Million | 71.18 Million | -3.2 Million | 9.64 Million |
| Free Cash Flow | -99.91 Million | -80.18 Million | -54.28 Million | -80.05 Million | -67.18 Million | -32.61 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -38.83 Million | -43.85 Million | -63.18 Million | -338.79 Million | -40.1 Million | -217.08 Million |
| Depreciation & Amortization | - | - | -220 Thousand | 744 Thousand | - | 580 Thousand |
| Deferred income taxes | - | - | -1.7 Million | 214.89 Million | - | 192.13 Million |
| Stock-based compensation | 8.68 Million | 13.83 Million | 17.27 Million | 25.67 Million | 4.78 Million | 1.91 Million |
| Change in working capital | -29.15 Million | 3.47 Million | -1.86 Million | -5.2 Million | -7.95 Million | 5.97 Million |
| Other non-cash items | -887 Thousand | 16.13 Million | 18.66 Million | 2.77 Million | 8.67 Million | -160 Thousand |
| Investing Cash Flow | -120.51 Million | -104.96 Million | -35.27 Million | -108.39 Million | -97.63 Million | 6.76 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | -15.47 Million | 3.03 Million | 15 Million | 475 Thousand |
| Investment purchases | -178.39 Million | -152.71 Million | -54.17 Million | -166.8 Million | -112.63 Million | - |
| Sales/Maturities of investments | 57.87 Million | 47.75 Million | 18.9 Million | 39.9 Million | - | 3.25 Million |
| Other Investing Activities | - | - | 15.47 Million | 15.47 Million | - | 3.03 Million |
| Financing Cash Flow | 360 Thousand | 172.16 Million | 163.6 Million | 361.07 Million | -12.53 Million | 209.99 Million |
| Debt repayment | - | - | - | -16 Thousand | - | -8000.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 360 Thousand | 173.59 Million | 169.11 Million | 169.11 Million | -12.53 Million | 210 Million |
| Other Financing Activities | 169.56 Million | -1.43 Million | -5.78 Million | -5.78 Million | - | - |
| Accounts receivables | - | - | 163 Thousand | 375 Thousand | 1.48 Million | -1.31 Million |
| Accounts payables | 6.63 Million | -4.29 Million | -783 Thousand | 218 Thousand | -1.04 Million | 661 Thousand |
| Inventory | - | - | -163 Thousand | -375 Thousand | -1.48 Million | 1.31 Million |
| Other working capital | -35.78 Million | 7.77 Million | -1.08 Million | -5.42 Million | -6.9 Million | 5.31 Million |
| Cash at beginning of period | 227.55 Million | 188.89 Million | 91.89 Million | 36.41 Million | 236.67 Million | 36.55 Million |
| Cash at end of period | 45.14 Million | 227.55 Million | 189.21 Million | 189.21 Million | 91.89 Million | 236.67 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | -4000.00 | 18 Thousand | 25 Thousand | -17 Thousand | 13 Thousand |
| Net cash flow / Change in cash | -182.4 Million | 38.65 Million | 97.31 Million | 152.79 Million | -144.77 Million | 200.12 Million |
| Free Cash Flow | -62.24 Million | -28.54 Million | -31.03 Million | -99.91 Million | -34.59 Million | -16.64 Million |
2050
PRD
ALBPK
AAIL
2015
VARN